Topical Imiquimod for the Treatment of Relapsed Cutaneous Langerhans Cell Histiocytosis after Chemotherapy in an Elderly Patient

Table 1

Report of topical imiquimod trials for cutaneous LCH.

References	Case; (age/gender)	Disease	Previous Rx		Topical; imiquimod; duration; (response)	Follow-up/outcome after finishing imiquimod
			Systemic chemotherapy	Topical Rx for skin LCH
Dodd and Hook [13]	16 mo/F	Isolated skin LCH alone	None	Corticosteroids/tacrolimus.	5 months; (CR)	>2 yrs; No relapse
Aubert-Wastiaux et al. [12]	4 yr/M	Simultaneous skin LCH with T-ALL	For T-ALL	None	1 month; (CHR)	Aggressive LCH; Died in <2 months
O’Kane et al. [11]	53 yr/F	Breast carcinoma, followed by isolated skin LCH	For breast carcinoma	None	6 weeks; (CHR)	Relapse after 6 months and then repeat imiquimod; CR for 12 months
Taverna et al. [10]	74 yr/F	Isolated skin LCH alone	None	Ketoconazole/hydrocortisone	2 months; (CR)	Relapse after 6 months and then repeat imiquimod
Current	61 yr/F	Skin LCH/CDI	For LCH ulcer	None	6.5 months; (CR)	>8 months; No relapse

LCH: Langerhans cell histiocytosis; ALL: acute lymphocytic leukemia; CDI: central diabetes insipidus; Rx: treatment; CR: clinical remission (not confirmed by biopsy after treatment); CHR: complete histological remission (confirmed by biopsy after treatment).